Clinical Trial

PCR for Aspergillus Fumigatus in Blood and Bronchoalveolar Lavage Fluid for Monitoring Cases of Invasive Aspergillosis: What is Its Prognostic Value

Study acronym: ASP
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 2, 2026 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
Aspergillus fumigatus PCR is currently used in conjunction with serum galactomannan to support the diagnosis of invasive aspergillosis or for monitoring at-risk patients not receiving antifungal prophylaxis. A positive result and a high titer are thought to be associated with the advanced stage of the disease and the fungal load. However, there is limited data on this subject, and no study has primarily focused on the variation of PCR levels during treatment and its potential correlation with treatment efficacy.
Trial Details
NCT Number NCT07313527
Lead Sponsor University Hospital, Strasbourg, France
Conditions Invasive Pulmonary Aspergillosis
Enrollment 100 participants
Start Date 2025-03-17
Primary Completion 2026-02 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2026-01-02